Gilead to seek pause in U.S. government HIV PrEP suit until patent office rules on patent validity

Gilead plans to ask a federal court to pause a patent infringement lawsuit the federal government filed against the company’s Truvada and Descovy HIV pre-exposure prophylaxis (PrEP) drugs pending resolution of Gilead’s patent challenges by the U.S. Patent and Trademark Office.

The lawsuit, filed Wednesday by the U.S. government in the U.S. District Court for the District of

Read the full 585 word article

User Sign In